SCHEMBL3969653

SCHEMBL3969653

OCn1c(C2CC2)nc2ccccc21

nearest known ligand 0.66

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.61
GAA P10253 1/20 0.61
USP2 O75604 1/20 0.57
POLB P06746 1/20 0.57
HRH1 P35367 9/20 0.54
CYP2D6 P10635 1/20 0.47
JAK2 O60674 1/20 0.46
JAK1 P23458 1/20 0.46
TYK2 P29597 1/20 0.46
JAK3 P52333 1/20 0.46
NOS3 P29474 1/20 0.46
NOS1 P29475 1/20 0.46
NOS2 P35228 1/20 0.46
CHRM1 P11229 1/20 0.45
GRM2 Q14416 1/20 0.45
MAPK1 P28482 1/20 0.45
KCNH2 Q12809 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3969006 0.94 USP2 (0.61) ALDH1A1GAAUSP2POLBHRH1
SCHEMBL7253536 0.83 ALDH1A1 (0.65) ALDH1A1GAAUSP2POLBHRH1
SCHEMBL31596383 0.81 USP2 (0.66) ALDH1A1GAAUSP2POLBHRH1
SCHEMBL31596378 0.81 ALDH1A1 (0.58) ALDH1A1GAAUSP2POLBHRH1
SCHEMBL31596376 0.80 ALDH1A1 (0.57) ALDH1A1GAAUSP2POLBHRH1
SCHEMBL12950771 0.78 HRH1 (0.61) ALDH1A1GAAUSP2POLBHRH1
SCHEMBL12950772 0.78 HRH1 (0.58) ALDH1A1GAAUSP2POLBHRH1
SCHEMBL24142608 0.77 HRH1 (0.76) ALDH1A1GAAUSP2POLBHRH1
SCHEMBL20715330 0.77 NPC1 (0.67) ALDH1A1GAACYP2D6NOS3NOS1
SCHEMBL24142446 0.77 ALDH1A1 (0.58) ALDH1A1GAAUSP2POLBHRH1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7595317-B2 Barbituric acid derivatives as inhibitors of TNF-α converting enzyme (TACE) and/or matrix metalloproteinases BRISTOL-MYERS SQUIBB COMPANY (US) 2009-09-29 US disclosed
US-7294624-B2 Osteoporosis; antiarthritic agents BRISTOL MYERS SQUIBB COMPANY (US) 2007-11-13 US disclosed
US-20070167451-A1 BARBITURIC ACID DERIVATIVES AS INHIBITORS OF TNF-alpha CONVERTING ENZYME (TACE) AND/OR MATRIX METALLOPROTEINASES DUAN JINGWU 2007-07-19 US disclosed
WO-2003053941-A2 BARBITURIC ACID DERIVATIVES AS INHIBITORS OF TNF-ALPHA CONVERTING ENZYME (TACE) AND/OR MATRIX METALLOPROTEINASES BRISTOL-MYERS SQUIBB COMPANY (US) 2003-07-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070167451-A1 BARBITURIC ACID DERIVATIVES AS INHIBITORS OF TNF-alpha CONVERTING ENZYME (TACE) AND/OR MATRIX METALLOPROTEINASES TNF, MMP9, MMP3 ALDH1A1 839/4885GAA 62/4885USP2 567/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.